Elisa Sottotetti

Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study

Mattia Boeri, Massimo Milione, Claudia Proto et al. · Clinical Cancer Research · 2019 · 82 citations · Full text

Medicine, Immunology, Oncology +17

DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan

Felicia Stefania Falvella, Stefania Cheli, Antonia Martinetti et al. · British Journal of Clinical Pharmacology · 2015 · 64 citations · Full text

Medicine, Oncology, Pharmacology +17

Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study

Paolo Manca, Salvatore Corallo, Sara Lonardi et al. · British Journal of Cancer · 2021 · 36 citations · Full text

Medicine, Genetics, Oncology +17

Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory,<i>RAS-BRAF</i>wild-type colorectal cancer receiving cetuximab or panitumumab

Valeria Musella, Filippo Pietrantonio, Eleonora Di Buduo et al. · International Journal of Cancer · 2015 · 35 citations · Full text

Medicine, Clinical Sciences, Oncology +17

Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

Somaieh Hedayat, Luciano Cascione, David Cunningham et al. · Clinical Cancer Research · 2024 · 33 citations

Medicine, Molecular Medicine, Oncology +17